 The FDA handed an accelerated approval to Seagen Inc NASDAQ: SGEN and Genmab AS NASDAQ: GMAB Tivdak tisotumab vedotin-tftv, or TV. The nod comes for second-line patients with recurrent or metastatic cervical cancer who previously progressed after chemotherapy rather than PD-L1 systemic therapy. 